{"organizations": [], "uuid": "3f75dea761a41837d9296e970169301c9bcd75c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alnylam-pharmaceuticals-q4-non-gaa/brief-alnylam-pharmaceuticals-q4-non-gaap-loss-per-share-1-20-idUSASB0C4S0", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.058, "site_type": "news", "published": "2018-02-08T21:07:00.000+02:00", "replies_count": 0, "uuid": "3f75dea761a41837d9296e970169301c9bcd75c7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alnylam-pharmaceuticals-q4-non-gaa/brief-alnylam-pharmaceuticals-q4-non-gaap-loss-per-share-1-20-idUSASB0C4S0", "ord_in_thread": 0, "title": "BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY\n* Q4 NON-GAAP LOSS PER SHARE $1.20 * EXPECTS TO END 2018 WITH APPROXIMATELY $1.0 BILLION IN CASH\n* REAFFIRMED GUIDANCE TO INITIATE A COMPREHENSIVE PHASE 3 PROGRAM FOR ALN-TTRSC02 IN LATE 2018\n* QTRLY LOSS PER SHARE $1.48 * REVENUES WERE $37.9 MILLION IN Q4 OF 2017, AS COMPARED TO $17.5 MILLION IN Q4 OF 2016\n* Q4 EARNINGS PER SHARE VIEW $-1.39 -- THOMSON REUTERS I/B/E/S\n* EXPECTS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $400 MILLION TO $440 MILLION\n* Q4 REVENUE VIEW $21.8 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T21:07:00.000+02:00", "crawled": "2018-02-09T16:51:41.001+02:00", "highlightTitle": ""}